Zaltrap is a biologic given with chemotherapy (FOLFIRI) for metastatic patients previously treated with oxaliplatin. Zaltrap is a tumor-starving (or anti-angiogenic) biologic therapy. Cancers need blood in order to grow. To get enough blood, tumors tell the body to grow new blood vessels. Angiogenesis inhibitors block this process. Zaltrap blocks a protein called vascular endothelial growth factor, or VEGF. Normal cells produce VEGF, but some cancer cells overproduce VEGF. Blocking VEGF may prevent the growth of new blood vessels that feed tumors.
Zaltrap is administered through an IV.
Common Side Effects
- Loss of appetite, nausea and/or vomiting
- Mouth sores and dry mouth